ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
11.19
-0.12
( -1.06% )
更新日時: 02:32:13

HUTCHMED China Limited (HCM) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
11.19
( -1.06% )
買値
11.12
売値
11.20
出来高
73,815
11.00 日の範囲 11.28
11.00 52 週間の範囲 19.50
時価総額
前日終値
11.31
始値
11.24
最終取引時間
02:50:25
財務取引量
US$ 826,659
VWAP
11.1991
平均取引量 (3 か月)
US$ 35,093
発行済株式数
859,744,319
配当利回り
PER
4.53
1 株当たり利益 (EPS)
0.52
歳入
548.51M
純利益
456.91M

HUTCHMED China Limited について

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor... HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. 詳細を表示

セクター
Healthcare
業界
Pharmaceuticals
ウェブサイト
本社
Hong Kong, Hong Kong
設立
2026
HUTCHMED China Limited is listed in the Healthcare sector of the ナスダック市場 with ticker HCM. The last closing price for HUTCHMED China was US$11.31. Over the last year, HUTCHMED China shares have traded in a share price range of US$ 11.00 to US$ 19.50.

HUTCHMED China currently has 859,744,319 shares in issue. The market capitalisation of HUTCHMED China is US$9.62 billion. HUTCHMED China has a price to earnings ratio (PE ratio) of 4.53.

HCM 最新ニュース

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.15-1.3227513227511.3411.731110628011.4031897DR
4-2.3-17.049666419613.4913.55115292411.8125479DR
12-3.26-22.560553633214.4515.79113905213.27680916DR
26-3.07-21.528751753214.2616.33113698113.89181706DR
52-3.63-24.493927125514.8219.5114372415.09872066DR
156-0.97-7.9769736842112.1621.9210.688884816.40569472DR
260-19.14-63.105835806130.3343.957.3920932718.40169165DR

HCM - Frequently Asked Questions (FAQ)

What is the current HUTCHMED China Limited share price?
The current share price of HUTCHMED China Limited is US$ 11.19
How many HUTCHMED China Limited shares are in issue?
HUTCHMED China Limited has 859,744,319 shares in issue
What is the market cap of HUTCHMED China Limited?
The market capitalisation of HUTCHMED China Limited is USD 9.62B
What is the 1 year trading range for HUTCHMED China Limited share price?
HUTCHMED China Limited has traded in the range of US$ 11.00 to US$ 19.50 during the past year
What is the PE ratio of HUTCHMED China Limited?
The price to earnings ratio of HUTCHMED China Limited is 4.53
What is the cash to sales ratio of HUTCHMED China Limited?
The cash to sales ratio of HUTCHMED China Limited is 3.7
What is the registered address of HUTCHMED China Limited?
The registered address for HUTCHMED China Limited is Cheung Kong Center, Hong Kong
What is the HUTCHMED China Limited website address?
The website address for HUTCHMED China Limited is www.hutch-med.com
Which industry sector does HUTCHMED China Limited operate in?
HUTCHMED China Limited operates in the Pharmaceuticals sector

HCM 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

HCM Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock